CAMBRIDGE, Mass., December 12, 2017
Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced the appointment of industry veteran Marc Jones as Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”).
In this dual role, Jones will lead Atlas Genetics’ finance and operations functions, as well as new channel development, and he will again partner with Jeffrey Luber, President and Chief Executive officer of Atlas, in key areas influencing strategic direction and execution.
“We are pleased to welcome Marc to the executive team as Atlas transitions from clinical proof of concept to its commercial phase globally,” said Luber. “The healthcare landscape is changing rapidly, with an emerging focus on consumer convenience and rapid testing in decentralized locations. With the Atlas io® platform’s ability to detect disease through a small, desktop instrument, we are poised to leverage these growing trends. Having talent of Marc’s caliber aboard, joining a stellar team of executives, will ensure we are ready to lead in new high-growth mobile/digital and retail health categories. Marc is a visionary executive with a proven track record of successfully guiding healthcare companies in new market categories through important commercial milestones. He has great skill in taking new ideas from concept to execution on time and on budget.”
Jones joins Atlas Genetics from Good Start Genetics, where he served as the COO and CFO. In that role, Jones and Luber raised successive rounds of capital and helped lead the turnaround of the company to record business growth and its ultimate sale to publicly traded Invitae (NYSE:NVTA).Prior to Good Start Genetics, Jones served as the CFO of T2 Biosystems, where he oversaw the company’s successful public offering, raising nearly $100 million in capital, and helped drive the commercialization of the company’s first FDA approved IVD product. Previously, Jones held the CFO position at Crashlytics, Ivenix and CHiL Semiconductor. Earlier in his career, he held a number of corporate finance positions ranging from Fortune 50 companies to high-growth startups.
About Atlas Genetics
Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-patient and point-of-care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-to-answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.
Atlas Genetics’investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.